Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Janssen wins FDA approval of twice-yearly schizophrenia treatment 

By Brian Buntz | September 1, 2021

JanssenJanssen (NYSE:JNJ) has won FDA approval for the long-acting atypical antipsychotic Invega Hafyera (paliperidone palmitate), which will be the first six-month injectable on the U.S. market.

Titusville, New Jersey–based Janssen announced that patients who intend to obtain Invega Hafyera must receive Invega Sustenna (one-month paliperidone palmitate) four at least four months beforehand. Alternatively, they can receive at least one cycle of Invega Trinza (three-month paliperidone palmitate).

While medication nonadherence is a challenge in all chronic conditions, the problem is especially acute in schizophrenia, as a 2014 study in Patient Related Outcome Measures explained. Schizophrenia can lead to social isolation, stigma, substance abuse, depression and cognitive impairment, all of which can complicate adherence.

Janssen is confident that twice-yearly Invega Hafyera could help address the issue.

FDA approved Invega Hafyera after reviewing data from the 12-month Phase 3 international study with 702 adults. The trial demonstrated that Invega Hafyera was non-inferior to Invega Trinza based on the primary endpoint of time to first relapse at the end of the 12-month interval.

The study found that 92.5% of Invega Hafyera recipients and 95% of Invega Trinza recipients were relapse-free at 12 months.

Drug developers have created a growing number of second-generation or atypical antipsychotics. Of those, only a handful are available as injections. In addition to Invega, other such drugs include Aripiprazole (Abilify Maintena, Aristada) from Otsuka Pharmaceutical, Fluphenazine decanoate from AuroMedics Pharma, and Janssen’s Haloperidol decanoate and Risperidone (Risperdal Consta and Perseris).


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: antipsychotics, FDA, Invega, Invega Hafyera, Janssen Pharmaceuticals, schizophrenia
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50